Monthly Archives:: December 2015

The world’s first guidelines for CPA have been published in the European Respiratory Journal by the ERS in conjunction with ESCMID. The guidelines cover the important features of this disease & comprehensive treatment and recommendations  for chronic pulmonary aspergillosis (CPA). This disease is fatal in about 80% of sufferers who succumb to this illness when their lungs… Read more »

In their latest UK report on Antimicrobial Resistance (AMR), Lord O’Neil and colleagues call for massive restraint in the use of both antibiotics in farmed animals and azole fungicides on crops. They call for “new classes of clinical antifungals that are developed in the future should be banned from use in food production. There might… Read more »

This week, Isavuconazole (Cresemba) will become available in Europe for the first time, following its recent launch in the USA. This is the first new antifungal agent launched for 9 years. It has a broad spectrum, intravenous and oral formulations, is required only once daily and a very good safety profile. Following the FDA approval… Read more »

  At the first ‘Histoplasmosis in the Americas and the Caribbean Meeting’ in Paramaribo Suriname, representatives from Latin America shared the dramatic problems of disseminated histoplasmosis in AIDS. The histoplasmosis problem exceeds the TB problem in many regions, and dwarfs malaria (<100 deaths annually across the Americas). One in 3 or 4 new AIDS admissions… Read more »

In May 2015, GAFFI issued a call to reduce AIDS deaths to under 500,000 by 2020 by provision of fungal diagnostics and antifungal therapies (GAFFI Roadmap).  In conjunction with increasing antiretroviral therapy coverage (90-90-90-  meaning action on fungal diseases will achieve a million more HIV survivors each year by 2020), diagnostics are also required for… Read more »